Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
Vaxart reported positive 12-month safety data from a 400-participant Phase 2b sentinel cohort, showing no vaccine-related serious adverse events for its oral pill COVID-19 vaccine compared to an approved mRNA comparator. While symptomatic COVID cases were similar between the oral pill and mRNA arms (33 vs 30), the company noted the cohort was not powered for comparative efficacy analysis.
Key figures
- Phase Of Trial
- Phase 2b
- Barda award value
- $344.8 million
- Main cohort participants
- 5000
- Sentinel cohort participants
- 400
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.